This work was supported by Schering-Plough and Pfizer, Inc. Editorial services were provided by Complete Healthcare Communications, Inc., and funded by Schering-Plough. RSM has received research funding from Wyeth, GlaxoSmithKline, Merck, Servier, and AstraZeneca; and has served as a consultant or speaker for AstraZeneca, Eli Lilly & Co., Janssen-Ortho, Schering-Plough, Wyeth, Lundbeck, GlaxoSmithKline, Oryx, Biovail, Pfizer, Prestwick, and Shire. MC, JZ, and JP are employees of Schering-Plough. LA and TAM were employed at Pfizer Global R&D at the time the study was conducted.
1399-5618/asset/bdi_centre.gif?v=1&s=3c4820d7ae483dbe851e246fcd2a5d3b113dac7c)
Asenapine versus olanzapine in acute mania: a double-blind extension study
Article first published online: 14 OCT 2009
DOI: 10.1111/j.1399-5618.2009.00749.x
© 2009 The Authors. Journal compilation © 2009 John Wiley & Sons A/S
Additional Information
How to Cite
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L., Macek, T. A. and Panagides, J. (2009), Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disorders, 11: 815–826. doi: 10.1111/j.1399-5618.2009.00749.x
Publication History
- Issue published online: 16 NOV 2009
- Article first published online: 14 OCT 2009
- Received 23 December 2008, revised and accepted for publication 5 July 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- asenapine;
- bipolar disorder;
- mania;
- olanzapine
Objective: To assess the efficacy and tolerability of asenapine versus olanzapine in the extended treatment of bipolar mania.
Methods: Patients with bipolar I disorder experiencing acute manic or mixed episodes who completed either of two 3-week, double-blind trials with asenapine 5 or 10 mg twice daily, olanzapine 5 to 20 mg once daily, or placebo were eligible for this 9-week, double-blind extension study. Patients receiving active medication in the 3-week trials continued the same regimen; those who had received placebo were blindly switched to asenapine but were assessed for safety outcomes only. The primary efficacy measure was the change from baseline to day 84 on the Young Mania Rating Scale (YMRS) total score in the per-protocol population. Results on the primary efficacy outcome were used to determine the noninferiority of asenapine versus olanzapine.
Results: A total of 504 patients (placebo/asenapine, n = 94; asenapine, n = 181; olanzapine, n = 229) were enrolled in the extension study. At day 84, the mean (SD) change from baseline in YMRS total score was −24.4 (8.7) for asenapine and −23.9 (7.9) for olanzapine. Prespecified statistical analysis for noninferiority indicated no significant difference between asenapine and olanzapine. The overall incidence of treatment-emergent adverse events was similar across treatment groups (77% placebo/asenapine, 77% asenapine, 78% olanzapine). Clinically significant weight gain occurred in 10%, 19%, and 31% of the placebo/asenapine, asenapine, and olanzapine groups, respectively.
Conclusions: Asenapine was efficacious, showed noninferiority to olanzapine, and was well tolerated in the extended treatment of patients experiencing manic symptoms associated with bipolar I disorder.